A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine

1996732 citationsJournal Articlebronze Open Access

Authors

Lennart Gustafsson · Sachs' Children and Youth Hospital

Elisabet Reizenstein · Swedish Institute

Jann Storsæter · Sachs' Children and Youth Hospital

Abstract

The five-component acellular pertussis vaccine we evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussis. The two-component acellular vaccine and the whole-cell vaccine were less efficacious.

Topics & Keywords

Bacterial Infections and Vaccines Pneumonia and Respiratory Infections Influenza Virus Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 334, Issue 6, pp. 349-356

DOI: 10.1056/nejm199602083340602

Field-Weighted Citation Impact: 43.45